Kytopen Appoints Paul K. Wotton, Ph.D. to Chair of Board of Directors
New Independent Board Chair, Dr. Paul K. Wotton, brings 35 years of experience building private and public biopharmaceutical companies with significant business development expertise.
Kytopen, an MIT-spin out and biotechnology company leading advancements in novel high-throughput cellular and genome engineering platforms, today announced the appointment of Paul K. Wotton, Ph.D. to Chair the Kytopen Board of Directors. Following the appointment of Dr. Wotton, the Board will comprise of five directors including Ann DeWitt, Adam Wieschhaus, Cullen Buie, and Paulo Garcia.
Dr. Paul Wotton received his Ph.D. in Pharmaceutical Sciences from the University of Nottingham and is an experienced CEO, Board Member, inventor, and serial entrepreneur. Dr. Wotton serves on the Board of Directors of Vericel Corporation (NASDAQ: VCEL) and Cynata Therapeutics (ASX: CYP) and is a Founder of Avenge Bio. Dr. Wotton was recently named as a “Top 100 Innovation CEO” by World Biz Magazine and won the Ernst & Young Entrepreneur of the Year Regional (NJ) Life Sciences award in 2014.
Paul Wotton, Ph.D. and new Chairman commented: “I am very pleased to join Kytopen at such an exciting time in our industry. Kytopen’s proprietary non-viral delivery technology solves a major bottleneck in the process of gene-modified cell therapy discovery, development, and manufacturing; a bottleneck that keeps costs high, limits productivity and constrains patient access to potentially life-saving medicines,”. Dr. Wotton continued “I’m honored to serve as the Chairman of Kytopen’s Board of Directors working alongside talented scientists, engineers and fellow Board members to expand on their growth strategy and technology designed to ultimately improve the lives of patients.”
Paulo Garcia, Ph.D., Kytopen Co-Founder and CEO said: “We are thrilled to welcome Paul Wotton to join and lead the Kytopen Board of Directors,” said Dr. Paulo Garcia, CEO and Co-Founder Kytopen. “Dr. Wotton not only brings significant experience growing biotech companies but also has the vision and aspiration to help Kytopen deliver on our mission to expand patient access to the next generation of living medicines.”
Kytopen is an MIT startup developing platforms to accelerate the discovery, development, and manufacturing of gene-modified cell therapies. The scalable Flowfect® solution combines microfluidics and automation to make this process easier, faster, and more cost-effective than the state-of-the art solutions. In 2017, Dr. Paulo Garcia co-founded Kytopen with Dr. Cullen Buie. Together they co-invented Kytopen’s proprietary Flowfect® technology for high-throughput genetic modification of cells. For more information, visit www.kytopen.com and follow @kytopen on Twitter and LinkedIn. Kytopen products are provided for Research Use Only.
Greg Crescenzi, CCO